Status:

UNKNOWN

NW Roselle in Grade 1 Essential Hypertension: Phase III Clinical Trial

Lead Sponsor:

Natural Wellness Egypt

Conditions:

Essential Hypertension

Eligibility:

All Genders

18-65 years

Phase:

PHASE3

Brief Summary

In this Phase III clinical trial, researchers evaluate the efficacy and safety of NW Roselle®, a powdered medicinal product developed by Natural Wellness. NW Roselle combines extracts from Hibiscus Sa...

Detailed Description

Hypertension is a major risk factor for heart, brain, and kidney diseases, and is a leading cause of death and illness globally. Natural Wellness has developed NW Roselle®, a powdered medicinal produc...

Eligibility Criteria

Inclusion

  • Diagnosed with grade 1 essential hypertension (Systolic Blood Pressure: 140-159 mmHg, and/or Diastolic Blood Pressure 90-99 mmHg) (Williams et al., 2018).
  • Not currently taking any medication for hypertension.
  • Able and willing to provide written informed consent.

Exclusion

  • Pregnant or lactating women.
  • Patients with BMI \> 45 Kg/m2 or BMI \< 18 Kg/m2.
  • Patients with a known history of secondary hypertension (e.g., hyperaldosteronism, pheochromocytoma, renal artery stenosis, Cushing syndrome).
  • Renal impairment (Estimated Creatinine Clearance (Cr.Cl.) \< 30 ml/min as measured by the Cockcroft-Gault formula).
  • Known Severe hepatic impairment, biliary cirrhosis, or cholestasis.
  • Patients with a history of arrhythmias, ischemic heart diseases, obstruction of the outflow tract of the left ventricle (e.g., hypertrophic obstructive cardiomyopathy, and high-grade aortic stenosis), congestive heart failure, valvular disease, myocardial infarction (MI), angina, myocardial revascularization, or cerebrovascular accident (CVA) within 6 months prior to study entry.
  • Participation in other clinical studies within 30 days before screening.
  • Known or suspected allergy or any contraindications to the trial products.

Key Trial Info

Start Date :

March 1 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

April 1 2025

Estimated Enrollment :

286 Patients enrolled

Trial Details

Trial ID

NCT06141200

Start Date

March 1 2024

End Date

April 1 2025

Last Update

November 21 2023

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

NW Roselle in Grade 1 Essential Hypertension: Phase III Clinical Trial | DecenTrialz